| Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277] | Technology appraisal guidance | TBC |
| Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314] | Technology appraisal guidance | TBC |
| Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable (MA partial review of TA663) [ID6291] | Technology appraisal guidance | |
| Venglustat for treating gangliosidoses in people 2 years and over ID 6358 | Technology appraisal guidance | TBC |
| Venoarterial extracorporeal membrane oxygenation (VA ECMO) for acute heart failure in adults | Interventional procedures guidance | |
| Venoarterial Extracorporeal membrane oxygenation (VA ECMO) for extracorporeal cardiopulmonary resuscitation (ECPR) in adults in refractory cardiac arrest | Interventional procedures guidance | |
| Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360] | Technology appraisal guidance | TBC |
| Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382] | Technology appraisal guidance | TBC |
| Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable TSID 12099 | Technology appraisal guidance | TBC |
| Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425] | Technology appraisal guidance | TBC |
| Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407] | Technology appraisal guidance | |
| Vosoritide for treating achondroplasia in people 4 months and over ID6488 | Technology appraisal guidance | TBC |
| VTS-270 for treating Niemann-Pick type C1 [ID1267] | Highly specialised technology | TBC |
| Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470] | Technology appraisal guidance | |
| Waldenstrom's macroglobulinaemia - ibrutinib [ID884] | Technology appraisal guidance | |
| Women's and reproductive health guidelines | NICE guideline | TBC |
| Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199] | Technology appraisal guidance | TBC |
| Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388] | Technology appraisal guidance | |
| Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392] | Technology appraisal guidance | |
| Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079] | Technology appraisal guidance | TBC |
| Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008] | Technology appraisal guidance | TBC |
| Zio XT for detecting cardiac arrhythmias | Medical technologies guidance | TBC |
| Zuranolone for treating postnatal depression [ID6431] | Technology appraisal guidance | |
| Venoarterial Extracorporeal membrane oxygenation (VA ECMO) for postcardiotomy cardiogenic shock in adults | Interventional procedures guidance | |